Sign In
NewsRadar

Press release centre

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.
   

Past Press Releases - SuppreMol

July 11, 2011
SuppreMol initiates Phase IIa clinical trial in Systemic Lupus Erythematosus (SLE) with its ...
SuppreMol initiates Phase IIa clinical trial in Systemic Lupus Erythematosus (SLE) with its lead candidate SM101 More

December 6, 2010
SuppreMol receives public research funding to advance its lead project SM101 into SLE
SuppreMol receives public research funding to advance its lead project SM101 into SLE as further indication More

April 19, 2010
SuppreMol receives U.S. orphan drug designation for SM101
SuppreMol, a company developing therapeutics for the treatment of autoimmune diseases, today announced that the FDA's Office of Orphan Products Development has granted Orphan Drug Designation for SuppreMol's lead product SM101, a recombinant human soluble Fcγ receptor IIb, for the treatment of Idiopathic Thrombocytopenic Purpura. More

September 7, 2009
SuppreMol receives public research funding for its lead project SM101
SuppreMol, a privately held biopharmaceutical company developing novel therapeutics for the treatment of autoimmune diseases, today announced it has been awarded research funding from the federal program 'KMU-Innovativ' by the German Federal Ministry of Education and Research (BMBF). More

May 4, 2009
SuppreMol announces start of phase I clinical trial with its lead program SM101
SuppreMol, a privately held biopharmaceutical company developing novel therapeutics for the treatment of autoimmune diseases, today announced the start of a Phase I clinical trial with its lead compound SM101. More

October 21, 2008
SuppreMol announces expansion of its management team and board changes
SuppreMol GmbH, a privately held biopharmaceutical company developing novel therapeutics for the treatment of autoimmune diseases, today announced the expansion of its management team as well as major changes in its Supervisory Board and Scientific Advisory Board. More

July 14, 2008
SuppreMol closes EUR 15.7 M Series B financing round
SuppreMol GmbH, a privately held biopharmaceutical company developing novel therapeutics for the treatment of autoimmune diseases, today announced that it has closed a EUR 15.7 million Series B financing round. More

Data


26,127
Tech investments
From our Online Data Service
16,882
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Sep 13N/AEnergy related
Sep 13€12.6MConsumer electronics
Sep 12€39.0MBiopharmaceuticals
Sep 12€2.3MInternet commerce
Sep 12€2.1MInternet services
Sep 12€4.0MMedical devices
Sep 12€9.0MSoftware development

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises 1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.